# Safety and Effectiveness of PANAF-Premium TM Snake Venom Antiserum As Standard Treatment for Snakebites

> **NCT06615960** · — · RECRUITING · sponsor: **Premium Serums & Vaccines Pvt.Ltd.** · enrollment: 112 (estimated)

## Conditions studied

- Snake Bites

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06615960
- **Lead sponsor:** Premium Serums & Vaccines Pvt.Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2025-02-26
- **Final completion:** 2025-04
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615960, "Safety and Effectiveness of PANAF-Premium TM Snake Venom Antiserum As Standard Treatment for Snakebites". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06615960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*